Literature DB >> 28363705

Relationship between plasma adropin levels and body composition and lipid characteristics amongst young adolescents in Taiwan.

Jin-Biou Chang1, Nain-Feng Chu2, Fu-Huang Lin1, Jhu-Ting Hsu1, Pi-Yun Chen1.   

Abstract

Adropin is a 76 amino acid peptide hormone with a molecular weight of 4999.9Da that may be associated with energy homeostasis, insulin resistance and lipid metabolism in mice and human. There is only a few studies that examine plasma adropin levels and body composition in children. This study is to evaluate the relationship between plasma adropin levels, body composition and lipid variables amongst young adolescents in Taiwan. We examined 492 adolescents (269 females and 223 males) ranging from 12 to 15 years old, with a mean age of 13.6 years. Body composition was measured using impedance method by Tanita-BC418. Plasma lipid variables were measured using standard methods and plasma adropin levels were measured using the ELISA method. There was no significant difference in plasma adropin levels between males and females (3.52 vs. 3.58ng/ml). Plasma adropin levels were negatively correlated with fat free mass (r=-0.12, p<0.01). More interestingly, children with higher plasma adropin levels had lower waist-to-hip ratios (WHR) and lower body fat percentage by mass. Furthermore, there is no difference in lipid profiles in high vs. low adropin subjects. Plasma adropin levels are not consistency associated with body composition and no association with lipid variables amongst Taiwanese adolescents. The role of adropin in the development of obesity is still not clear, and further studies are need especially for children.
Copyright © 2017 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adropin; Body composition; Children; Lipid

Mesh:

Substances:

Year:  2017        PMID: 28363705     DOI: 10.1016/j.orcp.2017.03.001

Source DB:  PubMed          Journal:  Obes Res Clin Pract        ISSN: 1871-403X            Impact factor:   2.288


  6 in total

1.  Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction.

Authors:  Subhashis Banerjee; Sarbani Ghoshal; Joseph R Stevens; Kyle S McCommis; Su Gao; Mauricio Castro-Sepulveda; Maria L Mizgier; Clemence Girardet; K Ganesh Kumar; Jose E Galgani; Michael L Niehoff; Susan A Farr; Jinsong Zhang; Andrew A Butler
Journal:  J Biol Chem       Date:  2020-07-29       Impact factor: 5.157

2.  Adropin and glucagon-like peptide-2 are associated with glucose metabolism in obese children.

Authors:  Rui-Min Chen; Xin Yuan; Qian Ouyang; Xiang-Quan Lin; Zhuan-Zhuan Ai; Ying Zhang; Xiao-Hong Yang
Journal:  World J Pediatr       Date:  2019-10-10       Impact factor: 2.764

3.  Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates.

Authors:  Andrew A Butler; Jinsong Zhang; Candice A Price; Joseph R Stevens; James L Graham; Kimber L Stanhope; Sarah King; Ronald M Krauss; Andrew A Bremer; Peter J Havel
Journal:  J Biol Chem       Date:  2019-04-15       Impact factor: 5.157

4.  Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Orkide Kutlu; Özgür Altun; Okan Dikker; Şerife Aktaş; Neslihan Özsoy; Yücel Arman; Eylem Özgün Çil; Mustafa Özcan; Şengül Aydın Yoldemir; Murat Akarsu; İlkim Deniz Toprak; Kerem Kırna; Yasin Kutlu; Zeki Toprak; Hasan Eruzun; Tufan Tükek
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

5.  Serum Adropin Levels in Patients on Hemodialysis.

Authors:  Dijana Boric-Skaro; Maja Mizdrak; Mirko Luketin; Dinko Martinovic; Daria Tokic; Marino Vilovic; Daniela Supe-Domic; Tina Ticinovic Kurir; Josko Bozic
Journal:  Life (Basel)       Date:  2021-04-11

6.  Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes.

Authors:  Agnieszka Polkowska; Izabela Elżbieta Pasierowska; Marta Pasławska; Elżbieta Pawluczuk; Artur Bossowski
Journal:  Biomed Res Int       Date:  2019-10-24       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.